A previous study reported by our laboratory revealed that HBV infection promotes PVTT development in HCC by activating and modifying the TGF-β-miR-34α-CCL22 pathway, which forms an immune-subversive micro-environment that enhances the colonization of cancerous cells in the portal vein (24). Here, CCL22 is linked to hepatocellular carcinoma.